Market closedNon-fractional
Celcuity/CELC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Ticker
CELC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Minneapolis, United States
Employees
55
Website
www.celcuity.com
Celcuity Metrics
BasicAdvanced
$672M
Market cap
-
P/E ratio
-$2.75
EPS
0.87
Beta
-
Dividend rate
Price and volume
Market cap
$672M
Beta
0.87
Financial strength
Current ratio
11.232
Quick ratio
10.641
Long term debt to equity
28.226
Total debt to equity
28.362
Interest coverage (TTM)
-13.89%
Management effectiveness
Return on assets (TTM)
-26.97%
Return on equity (TTM)
-57.17%
Valuation
Price to book
4.42
Price to tangible book (TTM)
4.42
Price to free cash flow (TTM)
-8.774
Growth
Earnings per share change (TTM)
5.58%
3-year earnings per share growth (CAGR)
42.27%
What the Analysts think about Celcuity
Analyst Ratings
Majority rating from 6 analysts.
Celcuity Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
14.89%
Profit margin
0.00%
NaN%
Celcuity Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.83
-$0.65
-$0.64
-
Expected
-$0.60
-$0.68
-$0.73
-$0.71
-$0.67
Surprise
10.46%
21.61%
-10.76%
-9.65%
-
Celcuity News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $672M as of July 26, 2024.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of July 26, 2024.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Celcuity stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.